Can serum periostin predict bronchopulmonary dysplasia in premature infants?
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
18
12
2020
accepted:
24
11
2021
revised:
23
11
2021
pubmed:
29
12
2021
medline:
26
10
2022
entrez:
28
12
2021
Statut:
ppublish
Résumé
Bronchopulmonary dysplasia (BPD) is the most common morbidity complicating preterm birth and affects long-term respiratory outcomes. The objectives of this study were to establish whether serum periostin at birth, day of life (DOL) 28, and corrected 36 weeks' gestational age could be potential biomarkers for BPD. A total of 98 preterm Japanese infants born at <32 weeks and comparing 41 healthy controls born at term, were divided into BPD (n = 44) and non-BPD (n = 54) cohorts. Serum periostin levels were measured using an enzyme-linked immunosorbent assay. Among 98 preterm infants, the median serum periostin levels at birth were higher with BPD (338.0 ng/mL) than without (275.0 ng/mL, P < 0.001). Multivariate analysis revealed that serum periostin levels at birth were significantly associated with BPD (P = 0.013). Serum periostin levels at birth with moderate/severe BPD (345.0 ng/mL) were significantly higher than those with non-BPD/mild BPD (283.0 ng/mL, P = 0.006). Serum periostin levels were significantly correlated with birth weight and gestational age, and serum periostin levels at birth in BPD infants were significantly higher than that in non-BPD infants. This study found higher serum periostin levels at birth in preterm infants subsequently diagnosed with bronchopulmonary dysplasia. It also emerged that serum periostin levels at birth significantly correlated with gestational age and birth weight. The mechanism by which serum periostin is upregulated in BPD infants needs further investigation.
Sections du résumé
BACKGROUND
Bronchopulmonary dysplasia (BPD) is the most common morbidity complicating preterm birth and affects long-term respiratory outcomes. The objectives of this study were to establish whether serum periostin at birth, day of life (DOL) 28, and corrected 36 weeks' gestational age could be potential biomarkers for BPD.
METHODS
A total of 98 preterm Japanese infants born at <32 weeks and comparing 41 healthy controls born at term, were divided into BPD (n = 44) and non-BPD (n = 54) cohorts. Serum periostin levels were measured using an enzyme-linked immunosorbent assay.
RESULTS
Among 98 preterm infants, the median serum periostin levels at birth were higher with BPD (338.0 ng/mL) than without (275.0 ng/mL, P < 0.001). Multivariate analysis revealed that serum periostin levels at birth were significantly associated with BPD (P = 0.013). Serum periostin levels at birth with moderate/severe BPD (345.0 ng/mL) were significantly higher than those with non-BPD/mild BPD (283.0 ng/mL, P = 0.006).
CONCLUSIONS
Serum periostin levels were significantly correlated with birth weight and gestational age, and serum periostin levels at birth in BPD infants were significantly higher than that in non-BPD infants.
IMPACT
This study found higher serum periostin levels at birth in preterm infants subsequently diagnosed with bronchopulmonary dysplasia. It also emerged that serum periostin levels at birth significantly correlated with gestational age and birth weight. The mechanism by which serum periostin is upregulated in BPD infants needs further investigation.
Identifiants
pubmed: 34961784
doi: 10.1038/s41390-021-01912-w
pii: 10.1038/s41390-021-01912-w
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1108-1114Informations de copyright
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Gough, A., Spence, D., Linden, M., Halliday, H. L. & McGarvey, L. P. A. General and respiratory health outcomes in adult survivors of bronchopulmonary dysplasia: a systematic review. Chest 141, 1554–1567 (2012).
pubmed: 22116801
doi: 10.1378/chest.11-1306
Gough, A. et al. Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia. Eur. Respir. J. 43, 808–816 (2014).
pubmed: 23900988
doi: 10.1183/09031936.00039513
Kinsella, J. P., Greenough, A. & Abman, S. H. Bronchopulmonary dysplasia. Lancet 367, 1421–1431 (2006).
pubmed: 16650652
doi: 10.1016/S0140-6736(06)68615-7
Baraldi, E. & Filippone, M. Chronic lung disease after premature birth. N. Engl. J. Med. 357, 1946–1955 (2007).
pubmed: 17989387
doi: 10.1056/NEJMra067279
Anderson, P. J. & Doyle, L. W. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin. Perinatol. 30, 227–232 (2006).
pubmed: 16860163
doi: 10.1053/j.semperi.2006.05.010
Izuhara, K. et al. Periostin in allergic inflammation. Allergol. Int. 63, 143–151 (2014).
pubmed: 24662806
doi: 10.2332/allergolint.13-RAI-0663
Izuhara, K. et al. Periostin: an emerging biomarker for allergic diseases. Allergy 74, 2116–2128 (2019).
pubmed: 30964557
doi: 10.1111/all.13814
Nanri, Y. et al. Cross-talk between transforming growth factor-β and periostin can be targeted for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 62, 204–216 (2020).
pubmed: 31505128
pmcid: 6993541
doi: 10.1165/rcmb.2019-0245OC
Yoshihara, T. et al. Periostin plays a critical role in the cell cycle in lung fibroblasts. Respir. Res. 21, 38 (2020).
pubmed: 32000779
pmcid: 6993476
doi: 10.1186/s12931-020-1299-0
Okamoto, M. et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur. Respir. J. 37, 1119–1127 (2011).
pubmed: 21177844
doi: 10.1183/09031936.00059810
Murata, K. et al. Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis. J. Thorac. Dis. 10, E587–E591 (2018).
pubmed: 30174940
pmcid: 6105951
doi: 10.21037/jtd.2018.06.96
Naik, P. K. et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 303, L1046–L1056 (2018).
doi: 10.1152/ajplung.00139.2012
Nakazawa, T. et al. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J. Orthop. Res. 22, 520–525 (2004).
pubmed: 15099630
doi: 10.1016/j.orthres.2003.10.007
Bozyk, P. D. et al. Neonatal periostin knockout mice are protected from hyperoxia-induced alveolar simplication. PLoS ONE 7, e31336 (2012).
pubmed: 22363622
pmcid: 3281961
doi: 10.1371/journal.pone.0031336
Ahlfeld, S. K., Davis, S. D., Kelley, K. J. & Poindexter, B. B. Early elevation of plasma periostin is associated with chronic ventilator-dependent bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 194, 1430–1433 (2016).
pubmed: 27905846
pmcid: 5148145
doi: 10.1164/rccm.201605-0910LE
Anderson, H. M. et al. Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development. J. Allergy Clin. Immunol. 139, 790–796 (2017).
pubmed: 27484037
doi: 10.1016/j.jaci.2016.05.033
Fujitani, H. et al. Age-related changes in serum periostin level in allergic and non-allergic children. Allergol. Int. 68, 285–286 (2019).
pubmed: 30711305
doi: 10.1016/j.alit.2018.12.006
Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723–1729 (2001).
pubmed: 11401896
doi: 10.1164/ajrccm.163.7.2011060
Itabashi, K., Miura, F., Uehara, R. & Nakamura New Japanese neonatal anthropometric charts for gestational age at birth. Pediatr. Int. 56, 702–708 (2014).
pubmed: 24617834
doi: 10.1111/ped.12331
Matsusaka, M. et al. Phenotype of asthma related with high serum periostin levels. Allergol. Int. 64, 175e80 (2015).
doi: 10.1016/j.alit.2014.07.003
Kimura, H. et al. Sinus computed tomographic findings in adult smokers and nonsmokers with asthma. Analysis of clinical indices and biomarkers. Ann. Am. Thorac. Soc. 14, 332e41 (2017).
doi: 10.1513/AnnalsATS.201606-463OC
Oak, P. & Hilgendorff, A. The BPD trio? Interaction of dysregulated PDGF, VEGF, and TGF signaling in neonatal chronic lung disease. Mol. Cell Pediatr. 4, 11 (2017).
pubmed: 29116547
pmcid: 5676585
doi: 10.1186/s40348-017-0076-8
Golpe, R. et al. Differences in systemic inflammation between cigarette and biomass smoke-induced COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 2639–2646 (2017).
pubmed: 28979110
pmcid: 5589102
doi: 10.2147/COPD.S141068
Pavlidis, S. et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur. Respir. J. 53, 1800938 (2019).
pubmed: 30578390
doi: 10.1183/13993003.00938-2018
Ahlfeld, S. K. et al. Periostin downregulation is an early marker of inhibited neonatal murine lung alveolar septation. Birth Defects Res. A Clin. Mol. Teratol. 97, 373–385 (2013).
pubmed: 23723163
pmcid: 4021395
doi: 10.1002/bdra.23149
Mokres, L. M. et al. Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice. Am. J. Physiol. Lung Cell Mol. Physiol. 298, L23–L35 (2010).
pubmed: 19854954
doi: 10.1152/ajplung.00251.2009
Hilgendorff, A. et al. Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth. Am. J. Physiol. Lung Cell Mol. Physiol. 303, L215–L227 (2012).
pubmed: 22683569
pmcid: 3423862
doi: 10.1152/ajplung.00405.2011
Go, H. et al. Extracellular vesicle miRNA-21 is a potential biomarker for predicting chronic lung disease in premature infants. Am. J. Physiol. Lung Cell Mol. Physiol. 318, L845–L851 (2020).
pubmed: 32191117
doi: 10.1152/ajplung.00166.2019
Kanemitsu, Y. et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J. Allergy Clin. Immunol. 132, 305e12 (2013).
doi: 10.1016/j.jaci.2013.04.050
Kudo, A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell Mol. Life Sci. 68, 3201–3207 (2011).
pubmed: 21833583
pmcid: 3173633
doi: 10.1007/s00018-011-0784-5
Aly, H. et al. Gestational age, sex and maternal parity correlate with bone turnover in premature infants. Pediatr. Res. 57, 708–711 (2005).
pubmed: 15774820
doi: 10.1203/01.PDR.0000160591.70409.C8
Zein, H. et al. Cord blood cytokine levels correlate with types of placental pathology in extremely preterm infants. Front. Pediatr. 9, 607684 (2021).
pubmed: 33777861
pmcid: 7991101
doi: 10.3389/fped.2021.607684
Romero, R. et al. Clinical chorioamnionitis at term V: umbilical cord plasma cytokine profile in the context of a systemic maternal inflammatory response. J. Perinat. Med. 44, 53–76 (2016).
pubmed: 26360486
pmcid: 5625297
Takayama, G. et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118, 98–104 (2006).
pubmed: 16815144
doi: 10.1016/j.jaci.2006.02.046
Baier, R. J., Loggins, J. & Kruger, T. E. Interleukin-4 and 13 concentrations in infants at risk to develop bronchopulmonary dysplasia. BMC Pediatr. 3, 8 (2003).
pubmed: 12925236
pmcid: 194674
doi: 10.1186/1471-2431-3-8
Perez, G. F. et al. Rhinovirus-induced airway cytokines and respiratory morbidity in severely premature children. Pediatr. Allergy Immunol. 26, 145–152 (2015).
pubmed: 25640734
pmcid: 5542573
doi: 10.1111/pai.12346
Kou, K. et al. Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. Br. J. Dermatol. 171, 283–291 (2014).
pubmed: 24601864
doi: 10.1111/bjd.12943
Ono, J., Takai, M., Kamei, A., Azuma, Y. & Izuhara, K. Pathological roles and clinical usefulness of periostin in type 2 inflammation and pulmonary fibrosis. Biomolecules 11, 1084 (2021).
pubmed: 34439751
pmcid: 8391913
doi: 10.3390/biom11081084